BRIEF-Cerevel Therapeutics Announces Positive Topline Results For Tavapadon In Phase 3 Adjunctive Trial For People Living With Parkinson’S Disease

Reuters04-18

April 18 (Reuters) - Cerevel Therapeutics Holdings Inc

* CEREVEL THERAPEUTICS ANNOUNCES POSITIVE TOPLINE RESULTS FOR TAVAPADON IN PHASE 3 ADJUNCTIVE TRIAL FOR PEOPLE LIVING WITH PARKINSON’S DISEASE

* CEREVEL THERAPEUTICS HOLDINGS INC: TAVAPADON MET PRIMARY ENDPOINT IN PIVOTAL PHASE 3 TEMPO-3 ADJUNCTIVE TRIAL

* CEREVEL THERAPEUTICS HOLDINGS INC - TAVAPADON MET PRIMARY ENDPOINT IN PIVOTAL PHASE 3

* CEREVEL THERAPEUTICS HOLDINGS INC - RESULTS FROM TAVAPADON PHASE 3 MONOTHERAPY TRIALS (TEMPO-1 AND TEMPO-2) ARE EXPECTED IN SECOND HALF OF 2024

* CEREVEL: STATISTICALLY SIGNIFICANT REDUCTION IN "OFF" TIME, KEY SECONDARY ENDPOINT, OBSERVED FOR TAVAPADON TREATMENT ARM

* CEREVEL THERAPEUTICS HOLDINGS INC - TAVAPADON WAS GENERALLY WELL TOLERATED

Source text for Eikon: Further company coverage:

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2428593829?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-04-18 20:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2428593829","market":"us","top_or_hot":-1,"title":"BRIEF-Cerevel Therapeutics Announces Positive Topline Results For Tavapadon In Phase 3 Adjunctive Trial For People Living With Parkinson’S Disease","media":"Reuters","content":"<html><body><p>April 18 (Reuters) - Cerevel <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Holdings Inc</p><p> :</p><p>   * CEREVEL THERAPEUTICS ANNOUNCES POSITIVE TOPLINE RESULTS FOR TAVAPADON IN PHASE 3 ADJUNCTIVE TRIAL FOR PEOPLE LIVING WITH PARKINSON’S DISEASE</p><p>   * CEREVEL THERAPEUTICS HOLDINGS INC: TAVAPADON MET PRIMARY ENDPOINT IN PIVOTAL PHASE 3 TEMPO-3 ADJUNCTIVE TRIAL</p><p>   * CEREVEL THERAPEUTICS HOLDINGS INC - TAVAPADON MET PRIMARY ENDPOINT IN PIVOTAL PHASE 3</p><p>   * CEREVEL THERAPEUTICS HOLDINGS INC - RESULTS FROM TAVAPADON PHASE 3 MONOTHERAPY TRIALS (TEMPO-1 AND TEMPO-2) ARE EXPECTED IN SECOND HALF OF 2024</p><p>   * CEREVEL: STATISTICALLY SIGNIFICANT REDUCTION IN \"OFF\" TIME, KEY SECONDARY ENDPOINT, OBSERVED FOR TAVAPADON TREATMENT ARM</p><p>   * CEREVEL THERAPEUTICS HOLDINGS INC - TAVAPADON WAS GENERALLY WELL TOLERATED</p><p>Source text for Eikon:    Further company coverage:   </p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Cerevel Therapeutics Announces Positive Topline Results For Tavapadon In Phase 3 Adjunctive Trial For People Living With Parkinson’S Disease</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Cerevel Therapeutics Announces Positive Topline Results For Tavapadon In Phase 3 Adjunctive Trial For People Living With Parkinson’S Disease\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-18 20:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>April 18 (Reuters) - Cerevel Therapeutics Holdings Inc :   * CEREVEL THERAPEUTICS ANNOUNCES POSITIVE TOPLINE RESULTS FOR TAVAPADON IN PHASE 3 ADJUNCTIVE TRIAL FOR PEOPLE LIVING WITH PARKINSON’S ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LENZ","symbol_name":"Therapeutics","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2428593829","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2428593829","pubTimestamp":1713443229,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"April 18  - Cerevel Therapeutics Holdings Inc :   * CEREVEL THERAPEUTICS ANNOUNCES POSITIVE TOPLINE RESULTS FOR TAVAPADON IN PHASE 3 ADJUNCTIVE TRIAL FOR PEOPLE LIVING WITH PARKINSON’S DISEASE   * CEREVEL THERAPEUTICS HOLDINGS INC: TAVAPADON MET PRIMARY ENDPOINT IN PIVOTAL PHASE 3 TEMPO-3 ADJUNCTIVE TRIAL   * CEREVEL THERAPEUTICS HOLDINGS INC - TAVAPADON MET PRIMARY ENDPOINT IN PIVOTAL PHASE 3   * CEREVEL THERAPEUTICS HOLDINGS INC - RESULTS FROM TAVAPADON PHASE 3 MONOTHERAPY TRIALS  ARE EXPECTED IN SECOND HALF OF 2024   * CEREVEL: STATISTICALLY SIGNIFICANT REDUCTION IN \"OFF\" TIME, KEY SECONDARY ENDPOINT, OBSERVED FOR TAVAPADON TREATMENT ARM   * CEREVEL THERAPEUTICS HOLDINGS INC - TAVAPADON WAS GENERALLY WELL TOLERATEDSource text for Eikon:    Further company coverage:","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LENZ":"Therapeutics","ARM":"ARM Holdings Ltd","BK4585":"ETF&股票定投概念","BK4139":"生物科技","BK4588":"碎股","BK4141":"半导体产品","CERE":"Cerevel Therapeutics Holdings, Inc."},"translate_title":"简介——Cerevel Therapeutics宣布Tavapadon在帕金森病患者3期辅助试验中的阳性顶线结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"CERE":0.9,"ARM":0.63},"content_text":"April 18 (Reuters) - Cerevel Therapeutics Holdings Inc :   * CEREVEL THERAPEUTICS ANNOUNCES POSITIVE TOPLINE RESULTS FOR TAVAPADON IN PHASE 3 ADJUNCTIVE TRIAL FOR PEOPLE LIVING WITH PARKINSON’S DISEASE   * CEREVEL THERAPEUTICS HOLDINGS INC: TAVAPADON MET PRIMARY ENDPOINT IN PIVOTAL PHASE 3 TEMPO-3 ADJUNCTIVE TRIAL   * CEREVEL THERAPEUTICS HOLDINGS INC - TAVAPADON MET PRIMARY ENDPOINT IN PIVOTAL PHASE 3   * CEREVEL THERAPEUTICS HOLDINGS INC - RESULTS FROM TAVAPADON PHASE 3 MONOTHERAPY TRIALS (TEMPO-1 AND TEMPO-2) ARE EXPECTED IN SECOND HALF OF 2024   * CEREVEL: STATISTICALLY SIGNIFICANT REDUCTION IN \"OFF\" TIME, KEY SECONDARY ENDPOINT, OBSERVED FOR TAVAPADON TREATMENT ARM   * CEREVEL THERAPEUTICS HOLDINGS INC - TAVAPADON WAS GENERALLY WELL TOLERATEDSource text for Eikon:    Further company coverage:","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2428593829"}